The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://monicauuba129013.ssnblog.com/37622177/retatrutide-vs-tirzepatide-a-comparative-analysis